These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6812851)

  • 21. The structure of cerebral cortex in the rat following prenatal administration of 6-hydroxydopamine.
    Lidov HG; Molliver ME
    Brain Res; 1982 Jan; 255(1):81-108. PubMed ID: 6799150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amphetamine-induced perseverative behavior in a radial arm maze following DSP4 or 6-OHDA pretreatment.
    Bruto V; Beauchamp C; Zacharko RM; Anisman H
    Psychopharmacology (Berl); 1984; 83(1):62-9. PubMed ID: 6429702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-hydroxydopamine and electrolytic lesions of the ascending dopamine systems of rat brain.
    Costall B; Marsden CD; Naylor RJ; Pycock CJ
    Brain Res; 1976 Dec; 118(1):87-113. PubMed ID: 990957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desmethylimipramine pretreatment prevents 6-hydroxydopamine induced somatostatin receptor reduction in the rat hippocampus.
    López-Sañudo S; Arilla E
    Regul Pept; 1992 Oct; 41(3):227-36. PubMed ID: 1438990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 6-hydroxydopamine on central noradrenaline neurons during ontogeny.
    Sachs C; Jonsson G
    Brain Res; 1975 Dec; 99(2):277-91. PubMed ID: 1182547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modification of different morphine actions by 6-hydroxydopamine and 6-hydroxydopamine plus desmethylimipramine.
    Fuchs V; Coper H
    Psychopharmacology (Berl); 1980 Feb; 67(2):181-8. PubMed ID: 6768093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Partial protection by desmethylimipramine of the mesocortical dopamine neurones from the neurotoxic effect of 6-hydroxydopamine injected in ventral mesencephalic tegmentum. The role of noradrenergic innervation.
    Herve D; Studler JM; Blanc G; Glowinski J; Tassin JP
    Brain Res; 1986 Sep; 383(1-2):47-53. PubMed ID: 3094831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altered effects of desipramine on operant performance after 6-hydroxydopamine-induced depletion of brain dopamine or norepinephrine.
    O'Donnell JM; Seiden LS
    J Pharmacol Exp Ther; 1984 Jun; 229(3):629-35. PubMed ID: 6427446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amphetamine reverses learning deficits in 6-hydroxydopamine-treated rat pups.
    Wool RS; Weldon DA; Shaywitz BA; Anderson GM; Cohen DJ; Teicher MH
    Dev Psychobiol; 1987 Mar; 20(2):219-32. PubMed ID: 3108057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of dopamine in the development of spontaneous hypertension.
    van den Buuse M; Versteeg DH; de Jong W
    Hypertension; 1984; 6(6 Pt 1):899-905. PubMed ID: 6519747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of hyperactivity in adult rats induced by neonatal intraventricular 6-hydroxydopamine following pargyline or desmethylimipramine treatment.
    Olds ME; Yuwiler A
    Psychopharmacology (Berl); 1985; 87(4):484-9. PubMed ID: 3936107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective catecholamine depletion of structures along the ventral lamina terminalis: effects on experimentally-induced drinking and pressor responses.
    Bellin SI; Landas SK; Johnson AK
    Brain Res; 1988 Jul; 456(1):9-16. PubMed ID: 3136861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catecholamine release by intracerebral perfusion of 6-hydroxydopamine and desipramine.
    Martin GE; Myers RD; Newberg DC
    Eur J Pharmacol; 1976 Apr; 36(2):299-311. PubMed ID: 1278225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of d-amphetamine and apomorphine upon operant behavior and schedule-induced licking in rats with 6-hydroxydopamine-induced lesions of the nucleus accumbens.
    Robbins TW; Roberts DC; Koob GF
    J Pharmacol Exp Ther; 1983 Mar; 224(3):662-73. PubMed ID: 6402587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine-norepinephrine interactions in the development of hyperphagia and obesity following medial hypothalamic lesions.
    Nobrega JN; Coscina DV
    Pharmacol Biochem Behav; 1986 Aug; 25(2):401-9. PubMed ID: 3094039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variability among brain regions in the specificity of 6-hydroxydopamine (6-OHDA)-induced lesions.
    Commins DL; Shaughnessy RA; Axt KJ; Vosmer G; Seiden LS
    J Neural Transm; 1989; 77(2-3):197-210. PubMed ID: 2503586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotyped behaviour patterns and hyperactivity induced by amphetamine and apomorphine after discrete 6-hydroxydopamine lesions of extrapyramidal and mesolimbic nuclei.
    Castall B; Marsden CD; Naylor RJ; Pycock CJ
    Brain Res; 1977 Mar; 123(1):89-111. PubMed ID: 300267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ascending catecholamine pathways and amphetamine-induced locomotor activity: importance of dopamine and apparent non-involvement of norepinephrine.
    Roberts DC; Zis AP; Fibiger HC
    Brain Res; 1975 Aug; 93(3):441-54. PubMed ID: 1236760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-dependent effects of 6-hydroxydopamine on locomotor activity in the rat.
    Erinoff L; MacPhail RC; Heller A; Seiden LS
    Brain Res; 1979 Mar; 164():195-205. PubMed ID: 427556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Central noradrenergic involvement in yohimbine excitation of acoustic startle: effects of DSP4 and 6-OHDA.
    Kehne JH; Davis M
    Brain Res; 1985 Mar; 330(1):31-41. PubMed ID: 3921192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.